Elsie

Elsie Biotechnologies is a San Diego-based biotechnology company specializing in the discovery and development of next-generation oligonucleotide therapeutics. The company's proprietary platform integrates advanced chemical synthesis, high-throughput screening, and data science to optimize RNA-based medicines for improved potency and safety. By exploring a massive chemical space of oligonucleotide analogs, Elsie aims to solve long-standing challenges in delivery and off-target toxicity. In June 2024, GSK acquired Elsie for up to $280 million following a successful research collaboration. This acquisition allows GSK to integrate Elsie's platform into its own R&D pipeline, particularly for treating complex diseases of the liver and infectious diseases. The company continues to operate as a key component of GSK's genetic medicine strategy.